I'm guessing most have seen this already, but thought I'd share in case you missed it:

Incredible Phase 3 results for VX-659!!!

From Vertex Press Release on 11/27:

Two Phase 3 Studies of the Triple Combination of VX-659, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis

-Mean absolute improvement in ppFEV1 of 14.0 percentage points from baseline at week 4 in people with one F508del mutation and one minimal function mutation compared to placebo (p<0.0001)-

-Mean absolute improvement in ppFEV1 of 10.0 percentage points from baseline at week 4 when VX-659 was added in people with two F508del mutations already receiving tezacaftor and ivacaftor compared to control group of placebo added to tezacaftor and ivacaftor (p<0.0001)-

-Safety and efficacy profile supports potential submission of a New Drug Application for the VX-659 triple combination regimen-

-Two Phase 3 studies of the triple combination of VX-445, tezacaftor and ivacaftor are now fully enrolled with data expected in the first quarter of 2019-

https://investors.vrtx.com/news-rele...tezacaftor-and